BridgeTower Capital Partners with Global Industry-Leading Art Fund Artemundi to Release NFT Series of Master Spanish Artist Francisco Goya
BridgeTower Capital, an innovator in connecting blockchain markets globally, announced a partnership with Artemundi, a leading global art fund, to release a series of NFTs featuring the work of acclaimed Spanish artist Francisco Goya. The announcement was made at the Avalanche Summit this week in Barcelona, where all live attendees received the NFT of Goya’s Caprice No. 6 titled, “No One Knows Each Other.”
“Francisco Goya is frequently recognized for his ability to portray the human condition and we believe this series of NFTs are a unique opportunity to bring the work of this Spanish Master to an entirely new audience for appreciation,” said Artemundi Chief Executive Officer Javier Lumbreras. “Goya’s work transcends time. This piece – Caprice No. 6 – shines light on our ability to effectively connect with each other. This has never been more relevant today and is at the core of our society within the expanding Metaverse.”
Caprice No. 6 is the first of a series of Goya NFTs that will be released over the next year and will be selected from 80 Caprices owned by Artemundi. Each will include an introduction about Goya, a description and translation title for all countries and a short, formal description of the symbolism of the piece. The NFTs will reside in the BridgeTower Permissioned Market, that investors can enter by creating a Securitize iD for a seamless KYC process that can be carried out in minutes. Securitize is a global leader in compliant issuance of digital assets and securities.
“It is an honor for BridgeTower to participate in this partnership with Artemundi celebrating the work of Francisco Goya,” said BridgeTower CEO Cory Pugh. “The BridgeTower Permissioned Market is a perfect place for these NFTs to reside and to create – through smart contracts within the Market – the proper asset ownership and authority for the investor.”
One of the most important elements of the Goya NFT collection will be the opportunities created for new and deeper interactions with a community of appreciation for Goya’s work. Discussion Forums will be built to discuss 21st Century interpretation of the Caprices, discussion of artistic expression, language, qualitative and subjective value of the Caprice. Additionally, a “how to see and appreciate your Goya Caprice” will be excerpted from the book The Art of Collecting Art, written by Javier Lumbreras.
The 21st Century relevance of the Goya masterpieces offer compelling themes that could be taken from today’s headlines. In addition to the Metaverse, upcoming Goya NFTs will feature themes including gender inequality, demagogue/fake news, freedom and the events in Ukraine.
“NFTs are just an incredible opportunity to participate in art in the 21st century,” continued Lumbreras. “It truly is a once-in-a-lifetime opportunity and we’re thrilled to be a part of this partnership between Artemundi and BridgeTower Capital.”
About BridgeTower Capital
BridgeTower Capital has developed a global platform to uniquely bring products to its own permissioned markets to seamlessly enable an institutional gateway to staking, DeFi, NFT and Web 3.0 entities. BridgeTower operates more than 5,000 of its own staking nodes and owns servers utilizing 100 percent renewable energy. Significant portions of returns from these products are reinvested to continually grow BridgeTower’s infrastructure and assets. BridgeTower is a global company based in Singapore with operating entities in Switzerland and the United States allowing it to compliantly address many of the most important jurisdictions in the global economy.
Learn more at http://www.bridgetowercapital.com.
About Artemundi
Artemundi was born out of a rebellious idea and a principled objective: to help their clients build and diversify their art investments without the excessive fees associated with traditional brick-and-mortar art companies while adhering to transparent business practices. Since its foundation in 1989, Artemundi has evolved into an industry-leading art investment company with thousands of successful transactions and over a billion dollars managed in art.
Learn more at https://artemundi.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005766/en/
Contact information
Media Contacts
BridgeTower: Todd Wolfenbarger, todd@bridgetowercapital.com
Artemundi: Daniel Fabris, Daniel.fabris@artemundi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom